Results 71 to 80 of about 3,892 (211)
British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2260-2271, July 2026.Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto +5 more
wiley +1 more source
LiversLong regarded as illicit substances with no clinical value, N-dimethylated tryptamines—such as N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and bufotenine—have been found to produce naturally in a wide variety of species, including humans ...
Hunter W. Korsmo
doaj +1 more source
Cancer Neuroscience: From Hallmark‐Enabling Biology to a Therapeutic Pillar
Advanced Oncology, Volume 1, Issue 1, December 2026.
Moran Amit
wiley +1 more source
Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada
Addiction, Volume 121, Issue 7, Page 1781-1793, July 2026.Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran +9 more
wiley +1 more source
Phenomenology of N,N-Dimethyltryptamine Use: A Thematic Analysis
, 2022 N,N-dimethyltryptamine (DMT) is an endogenous hallucinogenic compound in the same chemical class as the more common psilocybin and the neurotransmitter serotonin.
Rock, Adam J, Cott, Christopher
core
, 2020 N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT.
Perez-Castillo, Ana +14 more
core +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Phenomenology of N,N-Dimethyltryptamine use : a thematic analysis
, 2008 Phenomenology of N,N-Dimethyltryptamine use : a thematic ...
Adam Rock (13050294) +1 more
core
PsychoactivesPsychoactive drugs are compounds that alter the function of the central nervous system, resulting in changes in perception, mood, cognition, and behavior.
Jonathan Tran +4 more
doaj +1 more source
British Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source